07:00 , Sep 26, 2016 |  BC Week In Review  |  Clinical News

SRX246: Phase II data

The double-blind, U.S. Phase II AVN009 trial in 97 adults with intermittent explosive disorder showed that twice-daily 120 mg oral SRX246 for 4 weeks followed by twice-daily 160 mg oral SRX246 for 4 weeks was...
07:00 , May 16, 2016 |  BC Week In Review  |  Clinical News

SRX246: Completed Phase II enrollment

Azevan completed enrollment of 96 patients in a double-blind, placebo-controlled, dose-escalation, U.S. Phase II trial evaluating twice-daily oral SRX246 for 8 weeks. Patients receive 120 mg SRX246 for the first 4 weeks and 160 mg...
07:00 , Apr 9, 2015 |  BC Innovations  |  Strategy

Back to Basics at NIMH

NIH's National Institute of Mental Health is reversing the trend of promoting translational research in publicly funded organizations with a new strategic plan that formalizes the institute's recent shift back to basic research in its...
08:00 , Nov 14, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Excessive sleepiness Vasopressin 1a (V1a) receptor; V1b receptor Mouse studies suggest antagonizing the V1a or V1b receptors could be useful for treating sleep disturbance caused...
08:00 , Nov 17, 2008 |  BioCentury  |  Emerging Company Profile

Vantia: New irons in the fire

Vantia Therapeutics Ltd. spun out of Ferring Pharmaceuticals A/S with a portfolio of small molecules that includes a pair of vasopressin receptor modulators with disease-modifying potential. The company believes its lead program, a vasopressin 2...